Amgen Inc. (AMGN)

197.42
NASDAQ : Health Technology
Prev Close 196.44
Day Low/High 195.28 / 198.51
52 Wk Low/High 163.31 / 201.23
Avg Volume 2.62M
Exchange NASDAQ
Shares Outstanding 647.27M
Market Cap 127.15B
EPS 2.70
P/E Ratio 52.95
Div & Yield 5.28 (2.53%)

Latest News

Jim's Daily Rundown

Why we are buying gingerly on today's market decline.

Buying More Amgen Amid Wednesday's Broad Market Weakness

Big pharma firm looks good overall, but is falling with the rest of Wall Street.

Amgen: Cramer Discusses the AAP Portfolio's New Edition

Amgen: Cramer Discusses the AAP Portfolio's New Edition

In the August Action Alerts PLUS members' call, Jim Cramer and Jeff Marks, Senior Portfolio Analyst of Action Alerts PLUS, discuss the portfolio's new edition of Amgen.

Here's What Was Behind Monday's Selloff

The Dow Jones Industrial Average declined by 125 points on Monday.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Weekly Roundup

Markets end the week on a sour note.

Amgen Becomes #181 Most Shorted S&P 500 Component, Replacing S&P Global

Amgen Becomes #181 Most Shorted S&P 500 Component, Replacing S&P Global

The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Updates to Indices/Core Holdings and Notes From Today's Conference Call!

For those looking for the key takeaway of the call, herewith the 11 investing lessons we discussed.

Adding to Amgen, Trimming PayPal

We are adding to our Amgen position into today's weakness and financing it by reducing our PayPal holdings.

Buying Amgen on Weakness

We left ourselves plenty of room to take advantage of a down day like this.

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

Last Week's Portfolio Changes

We initiated a new position, raised a price target after earnings and upgraded the rating on another holding.

Weekly Roundup

Markets edged higher in what was a busy week from both a political and economic perspective.

Jim's Daily Rundown

Jim discusses earnings for DowDuPont and WestRock, our Amgen initiation, UnitedHealth Group, Kohl's, BP, Apple and more!

Scooping Up Shares of Amgen and BP

We have kept a healthy cash position to take advantage of down days like this.

Initiating Position in Amgen; Adding Again to Anadarko; Upgrading Kohl's

We are bringing AMGN out of the Bullpen and into the portfolio.

Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island

Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island

The Plant Will be First-of-its-Kind in the U.S.

Amgen Announces 2018 Third Quarter Dividend

Amgen Announces 2018 Third Quarter Dividend

THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.

Tech Rotation Hits Market; Bullpen Update

We are looking at today's rotation as an opportunity to pick up a high-quality name at a discount.

3 Best Ways to Play Amazon, Starbucks and Amgen After Earnings

3 Best Ways to Play Amazon, Starbucks and Amgen After Earnings

Here are 3 ways to play these 3 stocks on earnings.

Charting 3 Big Names After Earnings

Charting 3 Big Names After Earnings

How to play Amazon, Starbucks and Amgen on earnings news.

Amgen Announces Succession Plans For Two Executive Officers

Amgen Announces Succession Plans For Two Executive Officers

THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today.

Amgen Reports Second Quarter 2018 Financial Results

Amgen Reports Second Quarter 2018 Financial Results

THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018.

Facebook, Amazon, AMD, Qualcomm and PayPal - 5 Things You Must Know

Facebook, Amazon, AMD, Qualcomm and PayPal - 5 Things You Must Know

U.S. stock futures are mixed as investors react with caution to a broadly worded trade truce between the European Union and the United States; Facebook tanks as the social media giant points to slower growth; AMD swings to a profit; Qualcomm scraps deal for NXP.

Amgen Announces Webcast Of 2018 Second Quarter Financial Results

Amgen Announces Webcast Of 2018 Second Quarter Financial Results

THOUSAND OAKS, Calif., July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018, after the close of the U.

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

First Amgen Collaboration With Academic Medical Center Focused on Research, Health Service Redesign and Outcomes-Based Care

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

New Resources Available at MyelomaExplained.com Help Patients Set Goals and Prepare for Discussion With Doctor to Create Individualized Treatment Plan

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients

TheStreet Quant Rating: B (Buy)